Trial reportCancer immunology, immunotherapy : CII2024
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)
Trial report in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04571632 (A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis.Drug design, development and therapy · 2025Pooled it
- Radiotherapy and immunotherapy for advanced cancers: A meta-analysis of dose, sequencing, and survival patterns.Translational oncology · 2026Article
- Integrated approaches to sensitizing melanoma to radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- Synergizing Radiotherapy and Immune Checkpoint Inhibitors in Malignant Solid Tumours: Mechanistic Insights and Translational Frontiers.Expert reviews in molecular medicine · 2026Review
- Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer: 5-Year outcomes.JTCVS open · 2026Article
- Combinatorial approaches for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Immune remodeling of tumor-draining lymph nodes: mechanistic determinants of checkpoint blockade responsiveness.Frontiers in immunology · 2026Review
- Reframing the paradigm: stereotactic body radiation therapy as an engineer of the tumor immune microenvironment.Frontiers in immunology · 2026Review
- The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.Cancers · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1)
methodsIn this phase II clinical trial, anti-PD-1 ICB pretreated oligometastatic patients (tumor agnostic) underwent a leukapheresis followed by isolation of CD1c(BDCA-1)
resultsThirteen patients (10 in arm A, eight non-small cell lung cancer, and five melanoma) were enrolled. Two patients crossed over. One-year PFS rate was 10% in arm A and 0% in arm B. Two patients in arm A obtained a partial response, and one patient obtained a stable disease as best response. In arm B, one patient obtained a SD. Median PFS and OS were 21.8 weeks (arm A) versus 24.9 (arm B), and 62.7 versus 57.9 weeks, respectively. An iatrogenic pneumothorax was the only grade 3 treatment-related adverse event.
conclusionSBRT and pembrolizumab with or without IT avelumab/ipilimumab and IT myDC in oligometastatic patients are safe and feasible with a clinically meaningful tumor response rate. However, the study failed to reach its primary endpoint. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov: NCT04571632 (09 AUG 2020). EUDRACT: 2019-003668-32. Date of registration: 17 DEC 2019, amendment 1: 6 MAR 2021, amendment 2: 4 FEB 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.